Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706284 · ClinicalTrials.gov registry record · Phase 4
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
A Phase 4 study of Type 2 Diabetes and Spinal Cord Injuries, sponsored by Marzieh Salehi.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT06706284 is a Phase 4 study of Type 2 Diabetes and Spinal Cord Injuries that is actively recruiting participants, run by Marzieh Salehi. The registered enrollment target is 50 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06706284, a Phase 4 study of Type 2 Diabetes and Spinal Cord Injuries, is actively recruiting participants, sponsored by Marzieh Salehi.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Semaglutide Injectable Product
Study Locations (2)
Texas
- University Health - Texas Diabetic Institute - San Antonio
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-11 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06706284
The ClinicalTrials.gov registry entry for NCT06706284 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (95% lower). The listed sponsor is Marzieh Salehi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06706284 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06706284 about?
NCT06706284 is a clinical study titled "Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes". It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other informat...
What is the current status of trial NCT06706284?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-04-11. Estimated completion is 2029-01-01.
What conditions does trial NCT06706284 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Spinal Cord Injuries.
What interventions are being tested in trial NCT06706284?
The interventions under investigation include: Placebo (OTHER), Semaglutide Injectable Product (DRUG).
Who is sponsoring clinical trial NCT06706284?
This trial is sponsored by Marzieh Salehi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706284 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.